Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 468-478

  Ridderstråle, Martin ^a   Jensen, Marie Markert ^b   Gjesing, Rasmus Prior ^b   Niskanen, Leo ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NOVO NORDISK A S   (Denmark)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Hypoglycaemia; Insulin detemir; QALY; Type 2 diabetes; Weight gain

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; ISOPHANE INSULIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DENMARK; DIABETIC PATIENT; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FINLAND; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SWEDEN; WEIGHT GAIN;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FINLAND; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; SCANDINAVIA; WEIGHT GAIN;

EID: 84875748886     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.768999     Document Type: Article

References (53)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
5. Alvarez-Guisasola F, Yin DD, Nocea G, et al. Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes 2010;8:86
6. Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011;34:1164-70
7. Sommerfield AJ, Deary IJ, McAulay V, et al. Moderate hypoglycemia impairs multiple memory functions in healthy adults. Neuropsychology 2003; 17:125-32
8. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750-6
9. Diabetes Association Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-9
10. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
11. Hammer M, Lammert M, Mejias SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
12. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and metaanalysis. Diabetes Obes Metab 2011;13:1008-19
13. van Dieren S, Czernichow S, Chalmers J, et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012;14:464-9
14. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009; 52:65-73
15. Johnson WD, Brashear MM, Gupta AK, et al. Incremental weight loss improves cardiometabolic risk in extremely obese adults. Am J Med 2011;124:931-8
16. Ridderstra° le M, Gudbjornsdottir S, Eliasson B, et al. Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006;259:314-22
17. Gough SC, Kragh N, Ploug UJ, et al. Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. Diabetes Metab Syndr Obes 2009;2:179-84
18. Hlatky MA, Chung SC, Escobedo J, et al. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J 2010;159:292-300
19. Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin 2009;25:1985-93
20. Jendle J, Torffvit O, Ridderstra° le M, et al. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917-23
21. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
22. Valentine WJ, Aagren M, Haglund M, et al. Evaluation of the long-term costeffectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scand J Public Health 2011;39:79-87
23. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
24. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
25. Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
26. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
27. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
28. Currie CJ, Poole CD, Woehl A, et al. The health-related utility and healthrelated quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-80
29. Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospitaltreated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482-6
30. Regional Pay and Practitioners Tariff Board Organization Agreement. Agreement about general practice. 2010. http://www.medicinpriser.dk. Accessed March 21, 2012
31. Hujanen T, Kapiainen S, Tuominen U, et al. The unit cost of healthcare in Finland. 2006. http://asiakas.kela.fi/laakekys-app/LaakekysApplication? kieli1/4en. Accessed March 21, 2012
32. The Norwegian Medical Association. Normal tariff for private specialist practice 2011-2012. 2012. www.legemiddelverket.no. Acccessed March 21, 2012
33. Medicine prices in Sweden. 2012. http://www.tlv.se/beslut/sok-i- databasen. Accessed March 21, 2012
34. European Central bank. Danish krone (DKK). 2011. http://www.ecb.int/ stats/exchange/eurofxref/html/eurofxref-graph-dkk.en.html. Accessed December 6, 2011
35. European Central Bank. Norwegian krone (NOK). 2011. http://www.ecb.int/ stats/exchange/eurofxref/html/eurofxref-graph-nok.en.html. Accessed December 6, 2011
36. European Central Bank. Swedish krona (SEK). 2011. http://www.ecb.int/ stats/exchange/eurofxref/html/eurofxref-graph-sek.en.html. Accessed December 6, 2011
37. WHO Collaborating Centre for Drug Statistics Methodology. ATCC/DDD Index 2011. Norwegian Institute for Public Health, 2011. http://www.whocc.no/atc-ddd- index/. Accessed July 27, 2011
38. Keiding H, Færgeman O. Økonomiske konsekvensberegninger og tilskudsregler-belyst ved et eksempel. Ugeskrift for læger 2008;170:651-4
39. Lundin D. Kostnadseffektivitet som kriterium for subvention av lakemedel-en bra idé ? Ekonomiskdebatt 2004;6:32-40
40. Dagens Medicin. 2012. http://www.dagensmedisin.no/nyheter/kostnaderfor- ekstra-levear-forskjell-pa-eldre-og-yngre-/. Accessed May 8, 2012
41. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
42. National Institute for Clinical Excellence. Technology Appraisal Guidance No
43. Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine. London: National Institute for Clinical Excellence, 2002
44. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
45. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66
46. McEwan P, Poole C, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23:S21-S31
47. Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:273-90
48. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologies for treatment and prevention. 2008. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm071624.pdf. Accessed September 1, 2011
49. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
50. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005;22:749-55
51. Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92
52. Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202
53. Heller S. Nocturnal hypoglycaemia. In: Frier BM, Fisher M, eds. Hypoglycaemia in diabetes. 2nd ed. Chichester, UK: John Wiley & Sons Ltd, 2007. p 84-99